To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Inclusion criteria

• ✓. Patient with newly diagnosed, untreated histology-proven PTCL based on local pathology review who is eligible for receiving, Belinostat, Pralatrexate, and CHOP. Pathology material must be available at the site for each patient before enrollment so that it can be sent to the Sponsor (or designee) for later confirmation. The following subtypes, as defined by the updated World Health Organization (WHO) classification, may be included. This information should be available for eligibility:
• ✓. Pathology subtype:
• ✓. CD30 expression and T-cell Follicular Helper (TFH) phenotype status must be available for documentation.
• ✓. Patient has at least 1 site of measurable disease according to Response Evaluation Criteria in Lymphoma (RECIL) 2017 criteria as assessed by the local Investigator (Appendix 3)
• ✓. Patient has an Eastern Cooperative Oncology Group performance (ECOG) status ≤2
• ✓. For Part 1 (Dose Finding) - Patient has adequate hematological, hepatic, and renal function as defined by:
• ✓. Absolute neutrophil count ≥ 1.5 × 10⁹/L or ≥ 1.0 × 10⁹/L if evidence of bone marrow involvement
• ✓. Platelet count ≥100×10⁹/L or ≥ 75×10⁹/L if evidence of bone marrow involvement

Exclusion criteria